Longhorn Vaccines
Pre-clinicalLHNVD-501 is Longhorn’s lead product for preventing bacterial infections and sepsis. The antibody targets a key cell wall component that is also a toxin that alone and in synergy cause inflammation and chronic and debilitating disease.
Founded
2006
Focus
DiagnosticsVaccines
About
LHNVD-501 is Longhorn’s lead product for preventing bacterial infections and sepsis. The antibody targets a key cell wall component that is also a toxin that alone and in synergy cause inflammation and chronic and debilitating disease.
Funding History
5Total raised: $19.3M
Grant$1.8MNational Institute of Allergy and Infectious Diseases (NIAID)Jun 15, 2021
Series A$5MUndisclosedJun 15, 2021
Series A$10MUndisclosedJun 15, 2020
GrantUndisclosedUndisclosedJun 15, 2020
Company Info
TypePrivate
Founded2006
LocationBethesda, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile